The MHRA has launched a consultation into the best ways to engage and involve patients in its work, in order to develop a more systematic approach to engagement strategies.
Amongst other things, the Medicines and Healthcare products Regulatory Agency (MHRA) consultation will evaluate:
- how to give more weight to patient concerns about safety and licensing
- preferred communication methods between the public and the MHRA
- action that the public expect the MHRA to take in response to their concerns.
CEO of the MHRA, Dr Ian Hudson, has stressed the importance of the consultation:
“It is important that the MHRA continues to evaluate and improve how we can best communicate and engage with patients and the public.
“Patients are at the heart of everything we do and it’s essential that we hear their concerns and opinions to inform our important work protecting public health.
“Every response received will help us gain a better picture of how patients and the public want to engage with the MHRA. We hope to hear from as many people and patient groups as possible.”
Evidence from patients, patient group representatives, healthcare professionals and other interested parties is strongly encouraged, and the consultation closes on 7th October 2019.